MRKR
Marker Therapeutics, Inc.
$1.51
-0.07 (-4.43%)
At close · Jul 10
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$25.18M
Shares
16,673,127
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.51
Open$1.59
Day$1.51–1.59
52W$0.81–4.07
Avg vol 30d71K
Short int117K · 0.7% float · 2.2d
Short vol15%
Last earningsNov 10, 2021
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
+5%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
21%
mid-range
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−14%
trailing
YTD return
+1%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
1 of 36 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.70% of float · ▼ -46.4% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+34%
Y/Y
Free cash flow
$-12.4M
Balance sheet
$16.1M
net cash
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
21%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Flat
1 of 36 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.70% of float · ▼ -46.4% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 21%
52-wk high $4
vs 200-day avg +9%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRKR
this stock
Marker Therapeutics, Inc.
|
$25.18M | +1.3% | +99.1% | — | 0.7% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRKR | +2.7% | +5.6% | -14.2% | +2.7% | +1.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +1.4% | +1.5% | -23.3% | +1.6% | -9.4% |